Pfizer Inc. Stock
€27.54
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.860% | 3.866% | 6.148% | -18.158% | 5.517% | -20.794% | -24.013% |
| Johnson & Johnson | -0.420% | 3.448% | 2.199% | -6.985% | 0.438% | -0.975% | 22.498% |
| Elanco Animal Health Inc. | -0.490% | -7.742% | -30.809% | 7.930% | -13.624% | -61.357% | - |
| Biogen Inc. | -0.290% | -1.327% | -0.668% | -16.318% | -11.705% | -23.945% | 0.096% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage
2 Pharma Stocks to Buy Hand Over Fist This Month
Few pharmaceutical companies are more prominent than Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY). However, their popularity relative to most of their peers hasn't helped them much in the
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation
